Press release
Phost'in Therapeutics and the Gianni Bonadonna Foundation announce First Patients Dosed with the First-In-Class PhOx430 in an adaptive Phase I/II in patients with Advanced Solid Tumors
Montpellier, France – Sept 2022, 14th
Read more
Phost'in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona
Montpellier, France – June 2022, 07th
Read more
Phost'in Therapeutics joins TechShare 2022, Euronext's paneuropean Pre-IPO training program
Montpellier, France – Mars 2022, 09th
Read more
Phost’in Therapeutics announces €2.5m funding from Bpifrance to support regulatory and early clinical development of its First-In-Class N-Glycosylation Inhibitor
Montpellier, France – Sept 2020, 11th
Read more
In the news
€10M Series A Boosts Cancer Immunotherapy Hitting Tumor Sugar Coating
LABIOTECH.eu – April 2020, 22nd
Read more
Phost'in Therapeutics normalise la glycosylation des cellules tumorales
Les Echos – April 2020, 24th
Read more
Phost’In Therapeutics lève 10,3 M€ et démarre une étude clinique contre le cancer
La Tribune – Objectif LR – April 2020, 22nd
Read more
Karine Chorro, entrepreneuse en quête de sens
Le Journal Toulousain, Nov. 2019, 14th
Read more